In simple terms, a substance generally must meet one of these requirements: It has an official USP or National Formulary monograph It is already part of an FDA-approved drug product It appears on the FDAs official 503A Bulks List The important point is this: BPC-157, TB-500, and injectable GHK-Cu are not FDA-approved drugs, and they are not currently on the formal 503A Bulks List
These products often maintain moderate copper peptide concentrations (0.5% to 1%) to allow room for other active peptides
Maintain a mental or written record of site rotation
Does DSIP require a prescription
This makes it ideal for: Copper peptides Neuro-relaxing peptides Collagen-stimulating actives Skin-repairing serums When used correctly, it can improve peptide penetration by multiple folds compared to topical application alone
it is not the same as confirmation, and the same independent review is candid about the pharmacokinetic obstacles (discussed below) that stand between a conceivable mechanism and a working therapy